Trial
NCT04933942
Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
Amgen
Condition
First Progression of MGMT Promoter-methylated Glioblastoma
Intervention
Lomustine
Why stopped
Amgen withdrew interest in providing further financial support
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-24